{"entity":{"id":"vudalimab","kind":"drug","name":"Vudalimab","aka":[],"tldr":"Vudalimab is a bispecific antibody from Xencor, Inc., in registered phase 2 trials for ovarian cancer, endometrial cancer, cervical cancer.","summary":"Vudalimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Xencor, Inc., in ovarian cancer, endometrial cancer, cervical cancer, prostate cancer. A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Vudalimab","url":"https://clinicaltrials.gov/search?intr=Vudalimab"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["ovarian","endometrial","cervical","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["xencor"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05032040"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Bispecific antibody","mechanism":"A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vudalimab/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/"}],"trial":[{"id":"nct05032040","kind":"trial","name":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","route":"/trials/nct05032040/"}]}}